How QuantHub Rates Stock Quality and Valuation
Every long-term investor faces the same two questions about any stock: Is this a good business? Am I paying a fair price?
QuantHub rates every stock on both dimensions, independently. A great business can be overpriced. A cheap stock can be a declining business. Separating the two gives you a clearer framework for accumulation decisions.
What Quality means
Quality is about the business, not the stock price. We assign High, Medium, or Low Quality based on fundamental durability — the kind of characteristics that compound over years, not quarters.
High Quality means durable competitive advantages, consistent earnings growth, strong capital allocation, and management with a track record of execution. These are businesses you would want to own for five years regardless of short-term price action. Think wide moats: network effects, switching costs, pricing power, and expanding margins.
Medium Quality describes solid businesses with more cyclicality, execution risk, or competitive pressure. The fundamentals are sound but less predictable — perhaps strong revenue growth offset by margin volatility, or a dominant position in a commoditizing market.
Low Quality flags businesses that are commoditized, overleveraged, or in secular decline. Cheap does not fix a broken business model.
We synthesize this rating from financial data — revenue growth trends, margin stability, debt levels, return on equity, free cash flow consistency — combined with qualitative research on competitive positioning, management quality, and industry dynamics. The output is an investment grade (A through D) and a conviction level that maps directly to the Quality label you see on each research page.
What Valuation means
Valuation is purely about price versus our independent fair value estimate. A stock can be Cheap, Fair, or Expensive relative to what we calculate the business is worth — regardless of its Quality rating.
Our fair value methodology blends three approaches:
1. Relative valuation: Forward P/E using analyst consensus EPS estimates applied against the stock's own 3-year and 5-year median multiples. This anchors to how the market has historically valued this specific business. 2. Price-to-sales and price-to-free-cash-flow: Current ratios compared against 3-year and 5-year medians, identifying when a stock trades meaningfully above or below its own history. 3. Discounted cash flow: A 5-year projection of free cash flows, discounted to present value. We weight DCF conservatively because standalone DCF models exhibit high sensitivity to terminal assumptions.
The blended fair value is QuantHub's own estimate — not a Wall Street consensus target, not a single-model output. When current price sits materially below this estimate, the stock is Cheap. When price exceeds the estimate, it is Expensive. The valuation history on each stock page shows exactly where current multiples sit relative to multi-year medians.
Why they are separate
A great business at a terrible price is still a poor accumulation opportunity. A mediocre business at a bargain price is still a mediocre business.
Keeping Quality and Valuation independent lets you decide your own strategy. Some investors always pay up for the highest-quality businesses and rely on compounding to justify the premium. Others look for deep value regardless of quality. Most Patient Accumulators want both — and the filter on [/research](/research) lets you combine them to find exactly what matches your approach.
The sweet spot: Quality at a Discount
High Quality + Cheap is rare. When it appears, the cause is usually temporary — an earnings miss against elevated expectations, a sector rotation driven by macro sentiment, or broad market panic that drags down strong businesses alongside weak ones.
These moments are the Patient Accumulator's edge. A fundamentally excellent business that the market has temporarily mispriced is the highest-conviction accumulation opportunity we identify. Our [backtested signals](/scorecard) confirm this: A-rated companies trading below 60% of their 3-year valuation median with positive revenue growth have historically delivered meaningful alpha over the following six months.
On the [research page](/research), select High Quality and filter by valuation to surface these opportunities when they appear.
Explore the research
Every stock in our coverage universe has a full research page with Quality rating, fair value estimate, valuation history, and accumulation zones. The methodology described here is applied consistently across all coverage.
Browse the full library at [/research](/research), or [sign up](/signup) to receive Quality at a Discount signals delivered to your inbox every morning.